… International and Italian recommendations, scientific evidence on immunogenicity and
safety of DTaP/dTap vaccines to support the full dose as a pre-school booster and Italian …

… data from 6 clinical studies of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus
vaccine (DTaP-IPV [… The studies spanned a 15-year period (1995–2010) and were performed …

… In the studies with Pentaxim, combining PRP–T with the DTaP–IPV vaccines did not affect
the percentage of children who were seroprotected (anti-PRP titer ≥0.15 µg/ml), but the …

… Study Selection And Data Extraction: Phase 2 and 3 clinical trials evaluating immunogenicity
and safety of DTaP-IPV and DTaP-IPV/Hib were reviewed. Published trials … Data Synthesis: …

… The aim of this systematic literature review was to evaluate the immunogenicity, long-term
immunity and safety data currently available on DT2aP-IPV-Hib-HBV vaccination in infants. …

… to our knowledge? Delayed vaccination (at least 1 month) with the first dose of DTaP was …
Maternal pertussis vaccination accompanied with fewer and later doses of DTaP in children …

… This article summarizes the available safety, immunogenicity and effectiveness data of this
combination vaccine and provides a brief review of future trends in combination vaccine use. …

… DTaP-IPV/Hib vaccine administered at 15–16 versus 17–18 months of age (immunogenecity
data … Changes resulting from comments received were made on the basis of scientific and …

… study was to provide data on the co-administration of DTaP-IPV-HB-PRP-T and MenC
vaccine. The study was designed to assess the immunogenicity and safety of DTaP-IPV-HB-PRP-…

… Six studies that specifically evaluated the DTaP–IPV combination vaccine in children between
4 and 6 years of age have been published (Table 1) Citation[11]. Three were conducted in …